id: NEW:accumbal_glycine_levels_to_NEW:accumbal_dopamine_levels
name: Nucleus Accumbens Glycine Levels â†’ Nucleus Accumbens Dopamine Levels
from_node:
  node_id: NEW:accumbal_glycine_levels
  node_name: Nucleus Accumbens Glycine Levels
to_node:
  node_id: NEW:accumbal_dopamine_levels
  node_name: Nucleus Accumbens Dopamine Levels
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Elevated extracellular glycine in nucleus accumbens activates glycine receptors (GlyR)'
- 'Step 2: GlyR activation modulates dopaminergic neurotransmission in the mesolimbic pathway'
- 'Step 3: Dopamine levels are elevated in a subpopulation of animals (dopamine responders)'
- 'Step 4: Individual variability in dopamine response suggests heterogeneous receptor sensitivity'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Y. Olsson et al. 2020. "Effects of systemic glycine on accumbal glycine and dopamine
    levels and ethanol intake in male Wistar rats." https://doi.org/10.1007/s00702-020-02284-x
  supporting_citations:
  - Additional citations require full-text access - abstract references GlyR involvement in dopamine release
  - Abstract references prior work establishing GlyR role in basal and ethanol-induced dopamine release
  - Abstract references GlyT-1 inhibitor studies showing similar mechanisms
  doi: 10.1007/s00702-020-02284-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Elevated glycine levels in the nucleus accumbens modulate dopamine release through glycine
  receptor activation, though response varies by individual, with only a subpopulation showing dopamine
  elevation.
moderators:
- name: dopamine_responder_status
  direction: strengthens
  strength: strong
  description: Only a subpopulation of animals (dopamine responders) showed elevated accumbal dopamine
    levels after glycine treatment, indicating individual biological variability in response
structural_competency:
  equity_implications: Individual biological variability in treatment response has implications for personalized
    medicine approaches. Ensuring equitable access to pharmacogenomic testing and tailored treatments
    is essential for health equity.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.141148'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
